EDITAS MEDICINE INC (EDIT)
Health Care · CRISPR gene editing and genomic medicines · NASDAQ
A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL receptor upregulation.
What EDITAS MEDICINE INC does
Editas Medicine is a gene editing company developing CRISPR-based genomic medicines to treat serious genetic diseases. The company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a platforms to create in vivo gene editing therapies, with a focus on functional upregulation of normal genes through editing of non-coding regulatory sequences. Its lead candidate EDIT-401 is designed to treat hyperlipidemia by increasing LDL receptor expression to reduce LDL-cholesterol levels.
Themes: ["CRISPR gene editing","in vivo gene therapy","genomic medicines","rare genetic diseases","therapeutic gene regulation"]
Fundamentals
- Price$3.30 as of 2026-07-09 close
- Market cap$520M as of 2026-07-10
- 1-year return+7.1% as of 2026-07-09 close
- Net margin-281.6% as of 2026-07-10
- ROE-677.4% as of 2026-07-10
- Debt / equity12.40 as of 2026-07-10
- Revenue growth (YoY)+8.0% as of 2026-07-10
- Revenue CAGR (3y)+27.1% SEC XBRL
- Beta2.08 as of 2026-07-10
Key risks (from latest filing)
["Company is pre-commercial with only collaboration revenues; dependent on successful clinical development and regulatory approval of EDIT-401 and other pipeline candidates","Significant ongoing losses ($25M operating loss in Q1 2026) and negative net margins of -281.59% with declining cash reserves ($123.6M as of March 31, 2026)","Gene editing technology faces regulatory uncertainty, manufacturing scalability challenges, and potential off-target editing or immune response risks in human patients"]
Competitors & peers
- CRISPR Therapeutics (CRSP)
- Vertex Pharmaceuticals (VERX)
- Intellia Therapeutics (NTLA)
- Sangamo Therapeutics (SGMO)
- Beam Therapeutics (BEAM)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.